Epigenetics in the pathogenesis of rheumatoid arthritis by Tibor T Glant et al.
Cutting edge: issues in autoimmunity
Glant et al. BMC Medicine 2014, 12:35
http://www.biomedcentral.com/1741-7015/12/35COMMENTARY Open AccessEpigenetics in the pathogenesis of rheumatoid
arthritis
Tibor T Glant*, Katalin Mikecz and Tibor A Rauch*Abstract
An increasing number of studies show that besides the inherited genetic architecture (that is, genomic DNA), various
environmental factors significantly contribute to the etiology of rheumatoid arthritis. Epigenetic factors react to external
stimuli and form bridges between the environment and the genetic information-harboring DNA. Epigenetic mechanisms
are implicated in the final interpretation of the encoded genetic information by regulating gene expression, and
alterations in their profile influence the activity of the immune system. Overall, epigenetic mechanisms further increase
the well-known complexity of rheumatoid arthritis by providing additional subtle contributions to rheumatoid arthritis
susceptibility. Although there are controversies regarding the involvement of epigenetic and genetic factors in
rheumatoid arthritis etiology, it is becoming obvious that the two systems (genetic and epigenetic) interact with
each other and are ultimately responsible for rheumatoid arthritis development. Here, epigenetic factors and
mechanisms involved in rheumatoid arthritis are reviewed and new, potential therapeutic targets are discussed.
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More than 10 years after the completion of the human
genome sequencing project [1] and numerous genome-
wide association studies (GWAS) [2], we still do not fully
understand the genetic basis of rheumatoid arthritis (RA).
GWAS on patients with RA revealed more than 30
genomic risk loci, but identification of disease-promoting
genes and their functional characterization remain to be
accomplished [3,4]. The delayed progress in RA genetics
can be explained by the polygenic nature of the disease,
the enormous genetic heterogeneity of the human popula-
tion, and the difficulties with the interpretation of GWAS
data since most of the significant genetic alterations (that
is, mutations) are located in non-protein coding regions of
the genome. Another observation that raises some doubt
about a major role of genetic factors in RA pathogenesis is
that the concordance rate in monozygotic twins is only
approximately 15% [5]. However, twin studies drew atten-
tion to the importance of epigenetic factors that mediate
interactions between the genes and the environment [6-8].
In this commentary, we will first introduce the basic
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2014RA-related epigenetic studies. Finally, we will provide a
brief description of epigenetic factor-based future thera-
peutics in RA.Epigenetic regulation
Although there is no ‘carved-in-stone’ definition for
epigenetics, it is broadly defined as the study of heritable
changes in gene activity that do not involve any alterations
in the primary DNA sequence [9]. Epigenetics originally
focused on DNA methylation and various histone modifi-
cations, but recently expanded to the field of non-coding
RNAs. Ab ovo, each cell of the body inherits the same
genetic information. What makes each cell unique is
that, during ontogenesis, different sets of genes are
turned on and off. Epigenetic mechanisms establish the
proper nuclear milieu for cell-specific gene expression
and are responsible for the cellular memory, that is,
keeping and transmitting cell-specific gene expression
patterns to daughter cells. Epigenetic factors can deposit,
interpret and eliminate epigenetic information and, in this
sense, they can be divided into distinct functional groups:
epigenetic ‘writers’ or enzymes that modify DNA and
histones; epigenetic ‘readers’ with specific protein domains
that recognize DNA or histone marks; and epigenetictd. This is an Open Access article distributed under the terms of the Creative
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for new modifications (Figure 1A).
In studies on cancer and inflammatory and metabolic
disorders, frequent errors have been found in epigenetic
mechanisms that can result in the miswriting, misreading
or faulty removal of epigenetic signals [7].
DNA methylation is catalyzed by DNA methyltransferases
(writers) and associated with gene silencing [11]. DNA
methylation readers are the methyl-CpG-binding domain
proteins, which promote gene silencing by recruiting
histone modifiers. Erasers of DNA methylation have been
enigmatic for a long time, but recent studies have revealed
that demethylation proceeds via selective oxidation of
methylated cytosine residues, which is catalyzed by mem-
bers of the ten-eleven translocation protein family [12,13].
Genomic DNA and associated special nuclear proteins
(histones) comprise the nucleosomes that are the building
blocks of eukaryotic chromatin and the primary targets of
epigenetic modifiers [14]. We briefly describe the two best
characterized post-transcriptional modifications because
they have been already implicated in RA.
Histone acetylation and methylation exert their effects
on gene expression by regulating the accessibility of DNA
for transcription factors. As a general rule, modifications
decrease the compactness of chromatin structure and
promote gene expression (Figure 1B) [14]. Histone acetyl-
ation in any position favors transcription activation. Writers
are histone acetyltranferases (HATs), erasers are histoneFigure 1 Schematics of epigenome modifiers and chromatin
structure. (A) Post-translational modifications on histone tails.
Epigenetic signal writers are indicated in red, readers in green,
and erasers in blue. Acetylated lysine residues are represented by green
rectangles, methylated lysines by blue triangles and methylated CpGs
of genomic DNA by magenta circles. (B) States of the chromatin and
associated histone and DNA marks. The figure is original, with some
elements adapted from [10]. DNMTs, DNA methyltransferases; HATs,
histone acetyltranferases; HDACs, histone deacetylases; MBD,
methyl-CpG-binding domain; TET, ten-eleven translocation; TF,
transcription factor.deacetylases (HDACs), and bromodomain-containing pro-
teins are the readers of this type of histone modification.
Histone methylation represents a diverse set of epigenetic
signals [14] for at least three reasons: first, it can occur on
various residues (lysine or arginine); second, it exerts
its effect on transcription by determining the degree of
methylation (that is, mono-, di- or trimethylation); and
third, depending on the location of the modified residue,
histone methylation can either positively or negatively
affect gene expression. Histone methyltransferases, histone
demethylases and chromo-, Tudor- or plant homeodo-
main-containing proteins are the writers, erasers and
readers of this type of post-transcriptional modification, re-
spectively (Figure 1A). Different chromatin modifications
act together and a highly specific combination of various
post-transcriptional modifications creates the histone code
that ultimately determines the transcriptional status of a
gene [14].
Unlike genomic DNA (that is, genome), epigenetic
signals (that is, epigenome) are highly dynamic and show
cell type-specific patterns. Each type of cell has its own
characteristic epigenome profile with unique gene ex-
pression patterns; therefore, studies must be highly
specific regarding the investigated cell type.
Epigenetic alteration in rheumatoid arthritis synovial cells
Early studies found widespread DNA hypomethylation
in RA synovial fibroblasts, including hypomethylation of
the promoter of the CXCL12 gene [15] and the LINE1
retrotransposons [16] that are repetitive elements nor-
mally repressed by DNA methylation. In these cases, loss
of the repressive DNA methylation signal results in
increased gene expression. A recent genome-wide study
on RA synovial fibroblasts revealed a number of differen-
tially (hypo- and hyper-) methylated genomic regions [17].
Most of the affected genes appear to be involved in in-
flammation, matrix remodeling, leukocyte recruitment
and immune responses [17]. Another study found that
the HAT to HDAC activity ratio in arthritic joints was
shifted towards HAT dominance, favoring histone acetyl-
ation [18], ultimately leading to an increase in gene
transcription.
Epigenetic changes of the adaptive immune system
A genome-wide DNA methylation profiling study in per-
ipheral blood mononuclear cells reported differentially
methylated regions in the major histocompatibility complex
loci that make a significant contribution to the genetic risk
of developing RA [19]. Our group performed the first study
on arthritis-related epigenetic modifiers [20], in which
chromatin-modifying enzymes were analyzed in B and T
cells from arthritic mice and peripheral blood mononuclear
cells from patients with RA. All chromatin-modifying en-
zyme families were represented in the repertoire of genes
Figure 2 Therapeutic treatment of established proteoglycan-
induced arthritis (unpublished observations). Arthritic mice
(n = 10 per treatment) were divided into two groups with similar
mean severity scores and treated with 50 mg/kg anacardic acid or
vehicle alone (control) for 12 days. Arrows indicate the days of
treatment. The results shown are unpublished observations from
original research conducted in our laboratory. Values are the
mean ± standard error of the mean. *P <0.04; **P <0.01 ACA-treated
versus vehicle-treated groups. ACA, anacardic acid; PGIA,
proteoglycan-induced arthritis.
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acetyltransferases, deacetylases, methyltransferases and
demethylases, as well as ubiquitin ligases. The most
strongly upregulated genes were those encoding Aurora
kinase (A and B) enzymes in both arthritic animal and
human lymphocytes, and this was accompanied by
phosphorylation of serine 10 in the tail of histone H3.
This type of histone phosphorylation is a pivotal epigenetic
signal for the recruitment of the transcription factor nuclear
factor-kappaB (NF-κB) to the promoter of cytokine genes
[21], resulting in a cytokine-driven pro-inflammatory re-
sponse. We found that VX-680, an Aurora kinase-specific
inhibitor, significantly reduced the severity of arthritis and
promoted B cell apoptosis in the proteoglycan-induced
arthritis (PGIA) model of RA. The significance of VX-
680-induced B cell apoptosis is that patients with RA
who do not respond to anti-tumor necrosis factor therapy
are frequently treated with a monoclonal anti-CD20 anti-
body to eliminate autoantibody-producing B cells [22].
Our findings suggest that drug (VX-680)-induced B
cell depletion may provide an alternative to the CD20
antibody-based therapy.
In addition to Aurora kinases, several members of the
HAT family are also significantly upregulated in arthritic
mice and patients with RA, with the gene encoding Esco2
showing the strongest increase in expression. Esco2 is
thought to be required for the establishment of sister
chromatid cohesion and it also couples cohesion and
DNA replication to ensure that only sister chromatids
are paired together [23,24]. Because Esco2 belongs to
the HAT family of epigenetic modifiers, it is reasonable
to assume that it acts as a selective activator of certain
target genes. Anacardic acid (ACA) inhibits HATs [25]
and indirectly suppresses NF-κB activation [26]. We
tested the therapeutic potential of ACA in mice with
established PGIA. Mice treated with ACA displayed
significantly reduced arthritis progression as compared to
untreated control animals (unpublished observations;
Figure 2).
As described earlier, many of the epigenome modifiers
can directly or indirectly affect the activity of NF-κB, a
master regulator of the transcription of inflammation-
related genes. With regard to autoimmune or inflamma-
tory diseases such as RA, the emerging consensus is that
epigenetic factors (enzymes) supporting repressive signals
are downregulated, whereas those that promote transcrip-
tion are upregulated. A combination of these activities in
immune cells ultimately results in the strengthening of
pro-inflammatory pathways and the weakening of anti-
inflammatory mechanisms. For example, disease-linked
expression of KDM6B, a histone methyltransferase respon-
sible for eliminating a repressive epigenetic signal (that is,
histone H3 K27 trimethylation), is involved in macrophage
activation [27], and repression of the SETD6 gene, whichencodes a known negative regulator of NF-κB, leads to
runaway activity of this transcription factor [28].
The results of epigenetic studies in RA raise the question
whether the reported epigenetic alterations play a causative
role or are the consequences of other pathologic processes
that take place in RA. To answer this question, there is a
need for further epigenome-wide studies on all types of
cells involved in RA, exploration of a larger repertoire
of epigenetic signals, and investigation of the epigenetic
landscape at different phases of arthritis. It is possible
that significant advances will be achieved in the near future
because the technologies and model systems, including
genome and epigenome-wide analysis tools (such as
whole-genome sequencing, chromatin immunoprecipita-
tion sequencing and RNA sequencing) and animal models,
are readily available.
Information from RA-associated epigenetic studies can
be useful for diagnostic and therapeutic purposes because
investigation of the epigenetic landscape can provide both
potential biomarkers and therapeutic targets. There have
been numerous clinical trials involving patients with can-
cer that have tested such inhibitors as therapeutics against
malignancies [29]. Although we have demonstrated the
beneficial effect of specific Aurora kinase and HAT
inhibitors [20], and HDAC inhibitors have been tested by
other groups [30] in preclinical studies, unlike in the
cancer field, there is still no epigenetics-based drug on
the market of RA therapeutics.
Conclusions
A common outcome of genetic and epigenetic mutations
is that both ultimately lead to aberrant gene expression.
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expression are well known, including shorter or longer
deletions, insertions, inversions, translocations, or single
nucleotide changes within transcription factor binding
sites. Mutations hitting genes that encode epigenetic
regulators may result in aberrant expression or functional
impairment of the affected epigenetic factors [31-33].
The connection between epigenetically provoked and
epigenetics-independent genetic mutations is not obvious
and is currently under investigation. Both DNA hyper-
and hypomethylation can trigger genetic mutations. DNA
hypermethylation-mediated silencing of DNA repair genes
(for example, MGMT and MLH1) can result in inacti-
vation of cellular mechanisms responsible for keeping
the genetic mutation rate low [34,35] or in induction of
microsatellite instability as described in certain types of
cancer [36,37]. DNA hypomethylation can reactivate ret-
rotransposons (for example, long and short interspersed
nuclear elements), which then promote genetic mutations
by inserting extra nucleotides into the exons or regulatory
regions of genes [38,39].
Alteration in epigenetic mechanisms can trigger genetic
mutations and genetic mutations in epigenetic regulators
can lead to an altered epigenetic profile. Therefore, gen-
etics and epigenetics can be considered two sides of the
same coin, as has been established in the field of cancer
research [40]. It is very likely that in the near future the
same conclusion will be reached regarding autoimmune
diseases such as RA.
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